...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Long-term survival of composite hemiface/mandible/tongue allografts correlates with multilineage chimerism development in the lymphoid and myeloid compartments of recipients.
【24h】

Long-term survival of composite hemiface/mandible/tongue allografts correlates with multilineage chimerism development in the lymphoid and myeloid compartments of recipients.

机译:复合半面/下颌/舌舌同种异体移植物的长期存活与受体淋巴和髓样区室的多谱系嵌合现象发展有关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: To maximize aesthetic and functional outcomes for complex craniofacial defects, application of composite tissue allografts opens unique one-stage reconstructive option. We have assessed role of different components of the hemiface/mandible/tongue allograft on induction and maintenance of donor-specific chimerism, in correlation with allograft survival. METHODS: Twenty-two composite hemiface/mandible/tongue transplantations were performed in three groups: group 1 (n=8)-isotransplantations between Lewis (LEW) rats (RT1)-served as controls. Group 2 (n=8)-allograft rejection controls-hemiface/mandible/tongue transplants performed across major histocompatibility complex (MHC) barrier between semiallogeneic LEW-Brown-Norway (RT1) donors and LEW (RT1) recipients without immunosuppression. Allografts in group 3 (n=6) received tapered cyclosporine A monotherapy. Assessments included monitoring of rejection, flow cytometry for donor-specific chimerism of major histocompatibility complex class I (RT1) antigen, immunohistochemistry for engraftment of donor-origin cells into lymphoid organs and bone marrow (BM) compartment, and histology for hemiface/mandible/tongue architecture. RESULTS: Isograft controls survived indefinitely; in allografts without treatment, rejection started within 5 to 7 days. Treated hemiface/mandible/tongue allotransplants survived up to 385 days, without signs of rejection or graft loss. Flap angiography confirmed intact vascularity, and computer tomography scan and histology confirmed bone viability. Donor-specific chimerism at day 125 was present for T cells (3.3% CD4/RT1, 1.1% CD8/RT1) and B cells (6.7% CD45RA/RT1). Engraftment of donor-origin cells was confirmed into BM compartment and lymphoid organs of recipients. CONCLUSIONS: We introduced a new multitissue model of composite hemiface/mandible/tongue allograft containing lymphoid and vascularized BM components. Long-term allograft survival correlated with development and maintenance of donor-specific chimerism in lymphoid organs and BM compartment.
机译:背景:为了使复杂的颅面缺陷最大化美学和功能结果,复合组织同种异体移植的应用打开了独特的一阶段重建选项。我们已经评估了同种异体/下颌/舌同种异体的不同成分在同种异体移植存活率相关的诱导和维持供体特异性嵌合体中的作用。方法:三组共进行22例半脸/下颌/舌舌复合移植:第1组(n = 8)-Lewis(LEW)大鼠(RT1)之间的同种异体移植作为对照。第2组(n = 8)-同种异体移植排斥对照-半脸/下颌/舌舌移植在半同种异体LEW-Brown-Norway(RT1)供体与未免疫抑制的LEW(RT1)受者之间的主要组织相容性复合体(MHC)屏障上进行。第3组(n = 6)的同种异体移植接受锥形环孢素A单药治疗。评估包括监测排斥反应,流式细胞术检测主要组织相容性复合体I类(RT1)抗原的供体特异性嵌合体,供体来源细胞移植入淋巴器官和骨髓(BM)隔室的免疫组织化学以及半脸/下颌骨/舌头结构。结果:同种异体对照无限期存活;在未经治疗的同种异体移植物中,排斥反应在5至7天内开始。经处理的半脸/下颌/舌舌同种异体移植可以存活长达385天,没有排斥反应或移植物丢失的迹象。皮瓣血管造影证实了完整的血管,计算机断层扫描和组织学证实了骨的生存能力。在第125天,T细胞(3.3%CD4 / RT1,1.1%CD8 / RT1)和B细胞(6.7%CD45RA / RT1)出现供体特异性嵌合。证实供体来源的细胞已植入受体的BM区室和淋巴器官。结论:我们介绍了一种新的多组织模型,该模型包含同种半指/下颌/舌舌同种异体移植物,其中包含淋巴样和血管化的BM成分。同种异体移植物的长期存活与淋巴器官和BM区室中供体特异性嵌合体的形成和维持相关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号